Facebook
Twitter
LinkedIn
Forward
Advances in Non-Steroidal Topicals: PDE-4 Inhibitors for Seborrheic Dermatitis and Beyond
Traditional treatments for seborrheic dermatitis, including oral and topical steroids, present a variety of challenges including lack of efficacy, adverse events with long-term use, limitations for adherence, and the inability to treat both hair- and non-hair-bearing areas. Recently, the first targeted therapy for treatment of seborrheic dermatitis, a PDE-4 inhibitor topical foam, was approved by the FDA. Clinicians should be familiar with the latest clinical efficacy and safety data, as well as emerging data on the structural and molecular properties, for new PDE-4 inhibitor therapies, for current and emerging therapies to utilize them in clinical practice and capitalize on their treatment benefits.
This educational activity, originally presented at the 22nd Annual South Beach Symposium 2024, will focus on the pathophysiology of seborrheic dermatitis, mechanisms and clinical data for newly approved therapies, and key data regarding the molecular properties of new treatment options.
Target Audience
This activity is designed for an audience of physicians, nurses, and other advanced practice providers (nurse practitioners/physician assistants) in medical practices that specialize in dermatology and who treat seborrheic dermatitis.
Learning Objectives
Upon completion of the educational activity, participants should be better able to:
- Discuss the pathogenesis of seborrheic dermatitis and other inflammatory skin diseases and the role of specific inflammatory cytokines.
- Summarize the latest clinical safety and efficacy data for newly approved agents for treatment of seborrheic dermatitis.
- Interpret the latest molecular data comparing PDE-4 inhibitors for inflammatory skin diseases.
- Recording of Live Symposium
 |
Christopher Bunick, MD, PhD |
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse
0.75 ANCC contact hours.
Commercial Support
This activity is supported by an educational grant from Arcutis Biotherapeutics, Inc.
Disclosure
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
DISCLOSURES | ||
Name | Relationship | Commercial Interest |
Christopher Bunick MD, PhD | Consultant | AbbVie, Almirall, Apogee, Arcutis, Eli Lilly, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB |
Researcher | Abbvie, Almirall, Timber, Palvella | |
Dorothy Caputo, MA, BSN, RN, VP, Healthcare CE and Operations | N/A | Nothing to disclose |
Michele Bielarski, RN (planner/reviewer) | N/A | Nothing to disclose |
AKH Inc Staff and Planners | N/A | Nothing to disclose |
Tarsus dba LiVDerm Staff and Planners | N/A | Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated. | ||
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.
AKH Privacy Policy (link: https://akhcme.com/akhcme/pages/privacy
Available Credit
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.